INGN 225

Identification

Name
INGN 225
Accession Number
DB05325
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53. INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in breast cancer, head and neck cancer, and lung cancer.

Structured Indications
Not Available
Pharmacodynamics

INGN 225 uses the p53 tumor suppressor in a different manner than ADVEXIN to create a molecular immunotherapy for cancer that stimulates a particular type of immune system cell known as a dendritic cell. Testing has shown that the human immune system can recognize and kill tumors after treatment with dendritic cells stimulated by the p53 tumor suppressor, which suggests this therapy could have broad utility as a treatment for solid tumors. INGN 225 may also sensitize tumors to the effects of platinum and taxane chemotherapies.

Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with INGN 225.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 225.Experimental, Illicit
2-MethoxyethanolThe therapeutic efficacy of INGN 225 can be decreased when used in combination with 2-Methoxyethanol.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with INGN 225.Experimental, Illicit
AbataceptThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Abatacept.Approved
AbciximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Abciximab.Approved
AbetimusThe therapeutic efficacy of INGN 225 can be decreased when used in combination with abetimus.Investigational
AbituzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Abituzumab.Investigational
ActeosideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Acteoside.Investigational
AdalimumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Adalimumab.Approved
AdecatumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Adecatumumab.Investigational
AdefovirThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Adefovir.Investigational
AducanumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Aducanumab.Investigational
AfelimomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Afelimomab.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with INGN 225.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with INGN 225.Experimental, Investigational
AlefaceptThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Alemtuzumab.Approved, Investigational
AlicaforsenThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Alicaforsen.Investigational
AlirocumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Alirocumab.Approved
AltretamineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Altretamine.Approved
ALX-0081The therapeutic efficacy of INGN 225 can be decreased when used in combination with ALX-0081.Investigational
AmatuximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with INGN 225.Approved
AMG 108The therapeutic efficacy of INGN 225 can be decreased when used in combination with AMG 108.Investigational
AmsacrineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Amsacrine.Approved
AnakinraThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Anakinra.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with INGN 225.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with INGN 225.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with INGN 225.Investigational
AnifrolumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Anifrolumab.Investigational
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of INGN 225 can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).Approved
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of INGN 225 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).Approved
apolizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with apolizumab.Investigational
ApremilastThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Apremilast.Approved, Investigational
AscrinvacumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ascrinvacumab.Investigational
Asfotase AlfaThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with INGN 225.Investigational
AtezolizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Atezolizumab.Approved
AVE9633The therapeutic efficacy of INGN 225 can be decreased when used in combination with AVE9633.Investigational
AvelumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Avelumab.Approved
AzacitidineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with INGN 225.Approved
BapineuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Bapineuzumab.Investigational
BasiliximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Basiliximab.Approved, Investigational
BavituximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with INGN 225.Approved, Investigational
BectumomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Bectumomab.Investigational
BegelomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Begelomab.Experimental, Investigational
BelataceptThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Belatacept.Approved
BelimumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Belimumab.Approved
BenralizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Benralizumab.Approved
BenznidazoleThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Benznidazole.Approved, Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with INGN 225.Approved, Vet Approved
BevacizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Bevacizumab.Approved, Investigational
BIIB015The therapeutic efficacy of INGN 225 can be decreased when used in combination with BIIB015.Investigational
BimagrumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Bimagrumab.Investigational
bivatuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with bivatuzumab.Investigational
BleomycinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Bleomycin.Approved
BlinatumomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Blinatumomab.Approved
BlosozumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Blosozumab.Investigational
BococizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Bococizumab.Investigational
Brentuximab vedotinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Brentuximab vedotin.Approved
BriakinumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Briakinumab.Investigational
BrodalumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Brodalumab.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with INGN 225.Approved
BusulfanThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Busulfan.Approved, Investigational
CabazitaxelThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Cabazitaxel.Approved
CanakinumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Canakinumab.Approved, Investigational
CapecitabineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Capecitabine.Approved, Investigational
Capromab pendetideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Capromab pendetide.Approved
CarboplatinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Carboplatin.Approved
CarlumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Carlumab.Investigational
CarmustineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Carmustine.Approved
CastanospermineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Castanospermine.Experimental
CatumaxomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Catumaxomab.Approved, Investigational
Certolizumab pegolThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Certolizumab pegol.Approved
CetuximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Cetuximab.Approved
ChlorambucilThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Chlorambucil.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with INGN 225.Approved, Investigational
CisplatinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Cisplatin.Approved
CixutumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Cixutumumab.Investigational
CladribineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Cladribine.Approved, Investigational
ClazakizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Clazakizumab.Investigational
clenoliximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with clenoliximab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with INGN 225.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with INGN 225.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with INGN 225.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with INGN 225.Approved
ClofarabineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Clofarabine.Approved, Investigational
ConatumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Conatumumab.Investigational
ConcizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Concizumab.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with INGN 225.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with INGN 225.Experimental
CorticotropinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with INGN 225.Approved
CR002The therapeutic efficacy of INGN 225 can be decreased when used in combination with CR002.Investigational
CR011-vcMMAEThe therapeutic efficacy of INGN 225 can be decreased when used in combination with CR011-vcMMAE.Investigational
CrenezumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Crenezumab.Investigational
CrotedumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Crotedumab.Investigational
CyclophosphamideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Cyclophosphamide.Approved, Investigational
CyclosporineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with INGN 225.Approved, Investigational
Cytomegalovirus immunoglobulinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Cytomegalovirus immunoglobulin.Approved, Experimental
DacarbazineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Dacarbazine.Approved, Investigational
DacetuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Daclizumab.Approved, Investigational
DactinomycinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Dactinomycin.Approved
DalotuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Daratumumab.Approved
DasatinibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Dasatinib.Approved, Investigational
DaunorubicinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Daunorubicin.Approved
DeflazacortThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Deflazacort.Approved
DemcizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Demcizumab.Investigational
DenosumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Deoxyspergualin.Investigational
DepatuxizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Depatuxizumab.Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with INGN 225.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with INGN 225.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with INGN 225.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with INGN 225.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with INGN 225.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with INGN 225.Vet Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with INGN 225.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with INGN 225.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with INGN 225.Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with INGN 225.Approved, Investigational
DinutuximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Dinutuximab.Approved
DocetaxelThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Docetaxel.Approved, Investigational
DoxifluridineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Doxifluridine.Investigational
DoxorubicinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Doxorubicin.Approved, Investigational
DulaglutideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Dulaglutide.Approved
DuligotuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Duligotuzumab.Investigational
DupilumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Durvalumab.Approved
DusigitumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Dusigitumab.Investigational
EculizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Eculizumab.Approved, Investigational
EdrecolomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Edrecolomab.Experimental, Investigational
EfalizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Efalizumab.Approved, Investigational
ElotuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Emibetuzumab.Investigational
EpirubicinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Epirubicin.Approved
EpratuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with INGN 225.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with INGN 225.Approved
EstramustineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Estramustine.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with INGN 225.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with INGN 225.Approved
EtanerceptThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Etanercept.Approved, Investigational
EtaracizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Etaracizumab.Investigational
EtoposideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Etoposide.Approved
EtrolizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Everolimus.Approved
EvolocumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ficlatuzumab.Investigational
FigitumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Figitumumab.Investigational
FingolimodThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Fingolimod.Approved, Investigational
FirategrastThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Firategrast.Investigational
FloxuridineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with INGN 225.Investigational
FludarabineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Fludarabine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with INGN 225.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with INGN 225.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with INGN 225.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with INGN 225.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with INGN 225.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with INGN 225.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with INGN 225.Approved
FluorouracilThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with INGN 225.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with INGN 225.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with INGN 225.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with INGN 225.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with INGN 225.Approved
FontolizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with INGN 225.Approved, Investigational, Withdrawn
FresolimumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Fulranumab.Investigational
GaliximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Gallium nitrate.Approved, Investigational
GanitumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ganitumab.Investigational
GantenerumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Gantenerumab.Investigational
GemcitabineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Gemcitabine.Approved
Gemtuzumab ozogamicinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Gemtuzumab ozogamicin.Approved
GevokizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Gevokizumab.Investigational
Glatiramer AcetateThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Glatiramer Acetate.Approved, Investigational
GlimepirideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Glimepiride.Approved
GolimumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Golimumab.Approved
GS 0573The therapeutic efficacy of INGN 225 can be decreased when used in combination with GS 0573.Investigational
GuselkumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Guselkumab.Approved
GusperimusThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Gusperimus.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with INGN 225.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with INGN 225.Investigational
Human C1-esterase inhibitorThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Human C1-esterase inhibitor.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with INGN 225.Approved, Vet Approved
HydroxyureaThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Hydroxyurea.Approved
HypericinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Hypericin.Investigational
IbalizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ibalizumab.Investigational
Ibritumomab tiuxetanThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ibritumomab tiuxetan.Approved
IbrutinibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ibrutinib.Approved
IcatibantThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Icatibant.Approved
IdarubicinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Idarubicin.Approved
IdarucizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Idarucizumab.Approved
IdelalisibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Idelalisib.Approved
IfosfamideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ifosfamide.Approved
IGN311The therapeutic efficacy of INGN 225 can be decreased when used in combination with IGN311.Investigational
ImatinibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Imatinib.Approved
IMC-1C11The therapeutic efficacy of INGN 225 can be decreased when used in combination with IMC-1C11.Investigational
ImiquimodThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Imiquimod.Approved, Investigational
Immune Globulin HumanThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Immune Globulin Human.Approved, Investigational
InclacumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Inclacumab.Investigational
Indium In-111 satumomab pendetideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Indium In-111 satumomab pendetide.Approved, Withdrawn
InebilizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Inebilizumab.Investigational
InfliximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Infliximab.Approved
Inotuzumab ozogamicinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Inotuzumab ozogamicin.Approved
IntetumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Intetumumab.Investigational
IPH 2101The therapeutic efficacy of INGN 225 can be decreased when used in combination with IPH 2101.Investigational
IpilimumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ipilimumab.Approved
IrinotecanThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Irinotecan.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with INGN 225.Investigational
IxekizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ixekizumab.Approved, Investigational
L-PhenylalanineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with L-Phenylalanine.Approved, Nutraceutical
LabetuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Lampalizumab.Investigational
LandogrozumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Landogrozumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with INGN 225.Approved, Investigational
LenalidomideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Lenalidomide.Approved
lerdelimumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with lerdelimumab.Investigational
LexatumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Lexatumumab.Investigational
LigelizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ligelizumab.Investigational
LisofyllineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Lisofylline.Investigational
LomustineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Lomustine.Approved
Lorvotuzumab mertansineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Lorvotuzumab mertansine.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with INGN 225.Approved
LumiliximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Lumiliximab.Investigational
MatuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Matuzumab.Investigational
MavrilimumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mavrilimumab.Investigational
MDX-1100The therapeutic efficacy of INGN 225 can be decreased when used in combination with MDX-1100.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with INGN 225.Investigational
MechlorethamineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mechlorethamine.Approved
MEDI-528The therapeutic efficacy of INGN 225 can be decreased when used in combination with MEDI-528.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with INGN 225.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with INGN 225.Vet Approved
MelphalanThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Melphalan.Approved
MepolizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mepolizumab.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with INGN 225.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with INGN 225.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with INGN 225.Approved, Vet Approved
MilatuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Milatuzumab.Investigational
Mirvetuximab SoravtansineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MitomycinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mitomycin.Approved
MitoxantroneThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mitoxantrone.Approved, Investigational
MizoribineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mizoribine.Investigational
MogamulizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mogamulizumab.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with INGN 225.Approved, Vet Approved
MORAb-009The therapeutic efficacy of INGN 225 can be decreased when used in combination with MORAb-009.Investigational
motavizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with motavizumab.Investigational
MuromonabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Muromonab.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Mycophenolic acid.Approved
MYO-029The therapeutic efficacy of INGN 225 can be decreased when used in combination with MYO-029.Investigational
NafamostatThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Nafamostat.Approved, Investigational
Naptumomab EstafenatoxThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Naptumomab Estafenatox.Investigational
NatalizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with INGN 225.Investigational
NebacumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Nebacumab.Experimental
NecitumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Necitumumab.Approved
NelarabineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Nelarabine.Approved, Investigational
NilotinibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Nilotinib.Approved, Investigational
nimotuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with nimotuzumab.Investigational
NivolumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Obinutuzumab.Approved
OcrelizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ocrelizumab.Approved, Investigational
OfatumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Olaratumab.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with INGN 225.Investigational
OlokizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Olokizumab.Investigational
OmalizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Omalizumab.Approved, Investigational
OnartuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Otelixizumab.Investigational
OxaliplatinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Oxaliplatin.Approved, Investigational
OzanezumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ozanezumab.Investigational
PaclitaxelThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Paclitaxel.Approved, Vet Approved
PalbociclibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Palbociclib.Approved
PalivizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Panitumumab.Approved, Investigational
PanobinostatThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Panobinostat.Approved, Investigational
PaquinimodThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Paquinimod.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with INGN 225.Approved
PatritumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Patritumab.Investigational
PazopanibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pazopanib.Approved
PegaspargaseThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pegaspargase.Approved, Investigational
PembrolizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pembrolizumab.Approved
PemetrexedThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pemetrexed.Approved, Investigational
PentostatinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pentostatin.Approved, Investigational
PertuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PirarubicinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pirarubicin.Investigational
PirfenidoneThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pirfenidone.Approved, Investigational
Polatuzumab VedotinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Polatuzumab Vedotin.Investigational
PomalidomideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pomalidomide.Approved
PralatrexateThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Pralatrexate.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with INGN 225.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with INGN 225.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with INGN 225.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with INGN 225.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with INGN 225.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with INGN 225.Experimental, Investigational
PRO 140The therapeutic efficacy of INGN 225 can be decreased when used in combination with PRO 140.Investigational
PRO-542The therapeutic efficacy of INGN 225 can be decreased when used in combination with PRO-542.Investigational
ProcarbazineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Procarbazine.Approved
R1507The therapeutic efficacy of INGN 225 can be decreased when used in combination with R1507.Investigational
RacotumomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Raxibacumab.Approved
ReslizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Reslizumab.Approved, Investigational
RI 624The therapeutic efficacy of INGN 225 can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of INGN 225 can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Rilonacept.Approved
RilotumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with INGN 225.Approved
RituximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Rituximab.Approved
RobatumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Robatumumab.Investigational
RomosozumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Romosozumab.Investigational
RontalizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Rontalizumab.Investigational
RuxolitinibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ruxolitinib.Approved
Sacituzumab govitecanThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Sacituzumab govitecan.Investigational
SAR3419The therapeutic efficacy of INGN 225 can be decreased when used in combination with SAR3419.Investigational
SarilumabThe risk or severity of infection can be increased when Sarilumab is combined with INGN 225.Approved
SecukinumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Secukinumab.Approved
SemapimodThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Semapimod.Investigational
SeocalcitolThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Seocalcitol.Experimental, Investigational
SeribantumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Seribantumab.Investigational
SGN-40The therapeutic efficacy of INGN 225 can be decreased when used in combination with SGN-40.Investigational
SibrotuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Sibrotuzumab.Investigational
SiltuximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Siltuximab.Approved
siplizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with siplizumab.Investigational
SirolimusThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Sirolimus.Approved, Investigational
SirukumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Sirukumab.Investigational
SolanezumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Solanezumab.Investigational
SorafenibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Sorafenib.Approved, Investigational
SteproninThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Stepronin.Approved
StreptozocinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Streptozocin.Approved
SunitinibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Sunitinib.Approved, Investigational
SYM001The therapeutic efficacy of INGN 225 can be decreased when used in combination with SYM001.Investigational
TabalumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tabalumab.Investigational
TacrolimusThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tacrolimus.Approved, Investigational
TanezumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tanezumab.Investigational
TarextumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tarextumab.Investigational
TB-402The therapeutic efficacy of INGN 225 can be decreased when used in combination with TB-402.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Technetium Tc-99m arcitumomab.Approved, Investigational
TemozolomideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Temozolomide.Approved, Investigational
TemsirolimusThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Temsirolimus.Approved
TeniposideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Teniposide.Approved
TeplizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Teplizumab.Investigational
TepoxalinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Teriflunomide.Approved
Tetanus Immune GlobulinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tetanus Immune Globulin.Approved
ThalidomideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Thiotepa.Approved
TioguanineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tioguanine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with INGN 225.Approved
TNX-901The therapeutic efficacy of INGN 225 can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tocilizumab.Approved
TofacitinibThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tofacitinib.Approved, Investigational
TopotecanThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Topotecan.Approved, Investigational
TositumomabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tositumomab.Approved, Investigational
TovetumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tovetumab.Investigational
TrabectedinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Trabectedin.Approved, Investigational
TralokinumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tralokinumab.Investigational
TrastuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Trastuzumab emtansine.Approved
TRC105The therapeutic efficacy of INGN 225 can be decreased when used in combination with TRC105.Investigational
TremelimumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tremelimumab.Investigational
TretinoinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with INGN 225.Approved, Vet Approved
TriptolideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Triptolide.Investigational
TrofosfamideThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Trofosfamide.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with INGN 225.Approved
UstekinumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Ustekinumab.Approved, Investigational
VedolizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Vedolizumab.Approved
VeltuzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Veltuzumab.Investigational
VilanterolThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Vilanterol.Approved
VinblastineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Vinblastine.Approved
VincristineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Vincristine.Approved, Investigational
VindesineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Vindesine.Approved, Investigational
VinorelbineThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Vinorelbine.Approved, Investigational
VisilizumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Visilizumab.Investigational
VoclosporinThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Voclosporin.Investigational
volociximabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with volociximab.Investigational
XmAb 2513The therapeutic efficacy of INGN 225 can be decreased when used in combination with XmAb 2513.Investigational
XTL-001The therapeutic efficacy of INGN 225 can be decreased when used in combination with XTL-001.Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910082

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:23 / Updated on November 06, 2017 06:45